Premium
Mucosal immune network in the gut for the control of infectious diseases
Author(s) -
Iijima Hideki,
Takahashi Ichiro,
Kiyono Hiroshi
Publication year - 2001
Publication title -
reviews in medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.06
H-Index - 90
eISSN - 1099-1654
pISSN - 1052-9276
DOI - 10.1002/rmv.307
Subject(s) - intraepithelial lymphocyte , immunology , immune system , biology , antigen , mucosal immunology , cholera toxin , adjuvant , effector , chemokine , immunoglobulin a , antibody , cytotoxic t cell , immunity , microbiology and biotechnology , immunoglobulin g , biochemistry , in vitro
The common mucosal immune system (CMIS) consists of an integrated cross‐communication pathway of lymphoid tissues made up of inductive and effector sites for host protection against pathogenic microorganisms. Major effector molecules of the CMIS include IgA antibodies and cytokines, chemokines and their corresponding receptors. Secretory IgA (S‐IgA), the major immunoglobulin, is induced by gut‐associated lymphoreticular tissue (GALT)‐derived B cells with the help of Th1‐ and Th2‐type CD4 + T lymphocytes. Cytotoxic T lymphocytes (CTLs) in the mucosal epithelium, a subpopulation of intraepithelial lymphocytes (IELs), also help maintain the mucosal barrier. The CMIS is unique in that it can provide both positive and negative signals for the induction and regulation of immune responses in both the mucosal and systemic compartments after oral or nasal antigen exposure. Prevention of infection through mucosal surfaces can be achieved by the CMIS through connections between inductive (e.g. GALT) and effector tissues. When vaccine antigens are enterically administered together with mucosal adjuvants [e.g. cholera toxin (CT), heat‐labile toxin produced by Escherichia coli (LT) and IL‐12], antigen‐specific Th1/Th2 and IgA B cell responses are induced simultaneously in the mucosal effector compartment. Since these antigen‐specific immune responses are not generated by oral vaccine without mucosal adjuvant, safe and effective adjuvants for the induction of antigen‐specific S‐IgA and CTL responses are essential for the development of mucosal vaccines for protection against infectious diseases. Finally, recent findings suggest the presence of a CMIS‐independent IgA induction pathway, which also must be considered in the development of mucosal vaccines. Copyright © 2001 John Wiley & Sons, Ltd.